News
Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company
January 17, 2023
– The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in...
Read More
Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil
November 18, 2022
ROSEVILLE, Minn., Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed...
Read More
Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
November 17, 2022
ROSEVILLE, Minn., Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers...
Read More
Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 3, 2022
—Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants —Continued to progress customer acquisition activities, including...
Read More
Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing
November 1, 2022
Calyxt joins a select network of synthetic biology companies, top-tier academic institutions, research-focused not-for-profits, and US government agencies dedicated to...
Read More